Work

Patient profiles, treatment patterns and biomarker use in early-stage non-small cell lung cancer in Greece: the retrospective real-world INFINITY study

Year: 2026
Type: article
Study design: Observational Study
Abstract: This retrospective chart review study captured real-world initial management strategies and patient characteristics among those diagnosed with early-stage (stages I–IIIC) non-small cell lung cancer (NSCLC) between January 2016 and December 2020 at participating hospitals in Greece. This study describes management practices prior to the era of immuno-oncology therapy (IO) and targeted therapy (TT) in ES NSCLC. 300 patients were included, with equal representation of stages I, II, and III, excluding patients enrolled in clinical trials. Observation period extended from diagnosis until development of distant metastasis, withdrawal of consent, or death. Data was collected across 16 oncology clinics between October 2021 and May 2022. Median age at diagnosis was 67 years; 74% were male and 89% had a history of smoking. Most patients (96%) had a performance status of 0–1, and 62% had non-squamous histology. Biomarker testing was limited: 46% underwent any testing, including programmed death-ligand 1 (33%), epidermal growth factor receptor (31%), and anaplastic lymphoma kinase (28%). All but three patients received treatment. Surgical resection was performed in 75% of cases and systemic treatment in 74%, predominantly chemotherapy (91%). Radiotherapy was given to 29%. Overall, 68% received ≥ 2 treatment modalities. Among stage III patients, treatment appeared variable: 42% received definitive chemoradiotherapy without surgery, while among those who underwent surgery, 71% received adjuvant systemic treatment, 20% neoadjuvant, and 5% both. Most patients were treated with guideline-concordant modalities. These findings provide an essential historical baseline for evaluating evolving management patterns as novel systemic therapies are adopted into routine practice.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7235885994
FWCI:
Cites: 46
Cited by:
Related to: 10